New drug trial offers hope for Tough-to-Treat blood cancer

NCT ID NCT04162210

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new drug called belantamab mafodotin works better than the current standard treatment for people with multiple myeloma that has come back or stopped responding to other therapies. About 325 participants will be randomly assigned to receive either the new drug or the standard combination of pomalidomide and dexamethasone. The main goal is to see which treatment keeps the cancer from getting worse for a longer period of time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Tucson, Arizona, 85715, United States
GSK Investigational Site

Pueblo, Colorado, 81008, United States
GSK Investigational Site

Detroit, Michigan, 48202, United States
GSK Investigational Site

Omaha, Nebraska, 68130, United States
GSK Investigational Site

Clifton Park, New York, 12065, United States
GSK Investigational Site

Cincinnati, Ohio, 45236, United States
GSK Investigational Site

Corvallis, Oregon, 97330, United States
GSK Investigational Site

Eugene, Oregon, 97401, United States
GSK Investigational Site

Tyler, Texas, 75702, United States
GSK Investigational Site

Milwaukee, Wisconsin, 53226, United States
GSK Investigational Site

St Leonards, New South Wales, 2065, Australia
GSK Investigational Site

Hobart, Tasmania, 7000, Australia
GSK Investigational Site

Fitzroy, Victoria, 3065, Australia
GSK Investigational Site

Geelong, Victoria, 3220, Australia
GSK Investigational Site

Nedlands, Western Australia, 6009, Australia
GSK Investigational Site

Bruges, 8000, Belgium
GSK Investigational Site

Brussels, 1090, Belgium
GSK Investigational Site

Brussels, 1200, Belgium
GSK Investigational Site

Edegem, 2650, Belgium
GSK Investigational Site

Kortrijk, 8500, Belgium
GSK Investigational Site

Yvoir, 5530, Belgium
GSK Investigational Site

Porto Alegre, Rio Grande do Sul, 90035-903, Brazil
GSK Investigational Site

Curitiba, 80530-010, Brazil
GSK Investigational Site

Fortaleza, 60115-281, Brazil
GSK Investigational Site

Porto Alegre, 90110-270, Brazil
GSK Investigational Site

Rio de Janeiro, 22793-080, Brazil
GSK Investigational Site

São Paulo, 01321001, Brazil
GSK Investigational Site

São Paulo, 01509-900, Brazil
GSK Investigational Site

São Paulo, 04537-080, Brazil
GSK Investigational Site

São Paulo, 05651-901, Brazil
GSK Investigational Site

Sofia, 1606, Bulgaria
GSK Investigational Site

Edmonton, Alberta, T6G 1Z2, Canada
GSK Investigational Site

Beijing, 100000, China
GSK Investigational Site

Beijing, 100050, China
GSK Investigational Site

Beijing, 100730, China
GSK Investigational Site

Chengdu, 610041, China
GSK Investigational Site

Hangzhou, 310009, China
GSK Investigational Site

Nanchang, 330006, China
GSK Investigational Site

Shenzhen, 518029, China
GSK Investigational Site

Tianjin, 300020, China
GSK Investigational Site

Tianjin, 300060, China
GSK Investigational Site

Xuzhou, 221006, China
GSK Investigational Site

Zhengzhou, 450052, China
GSK Investigational Site

Le Mans, 72015, France
GSK Investigational Site

Montpellier, 34295, France
GSK Investigational Site

Poitiers, 86021, France
GSK Investigational Site

Berlin, 13125, Germany
GSK Investigational Site

Tübingen, 72076, Germany
GSK Investigational Site

Athens, 10676, Greece
GSK Investigational Site

Athens, 115 28, Greece
GSK Investigational Site

Haidari - Athens, 12462, Greece
GSK Investigational Site

Larissa, 41 110, Greece
GSK Investigational Site

Pátrai, 26500, Greece
GSK Investigational Site

Thessaloniki, 54007, Greece
GSK Investigational Site

Thessaloniki, 57010, Greece
GSK Investigational Site

Budapest, 1083, Hungary
GSK Investigational Site

Budapest, 1088, Hungary
GSK Investigational Site

Budapest, 1097, Hungary
GSK Investigational Site

Debrecen, 4012, Hungary
GSK Investigational Site

Kaposvár, 7400, Hungary
GSK Investigational Site

Nyíregyháza, 4400, Hungary
GSK Investigational Site

Brescia, 25123, Italy
GSK Investigational Site

Catanzaro, 88100, Italy
GSK Investigational Site

Milan, 20122, Italy
GSK Investigational Site

Milan, 20141, Italy
GSK Investigational Site

Pavia, 27100, Italy
GSK Investigational Site

Perugia, 05100, Italy
GSK Investigational Site

Ravenna, 48123, Italy
GSK Investigational Site

Roma, 00161, Italy
GSK Investigational Site

San Giovanni Rotondo FG, 71013, Italy
GSK Investigational Site

Siena, 53100, Italy
GSK Investigational Site

Shibuya-Ku, Tokyo, 150-8935, Japan
GSK Investigational Site

Aichi, 467-8602, Japan
GSK Investigational Site

Chiba, 277-8567, Japan
GSK Investigational Site

Ehime, 790-8524, Japan
GSK Investigational Site

Fukushima, 960-1295, Japan
GSK Investigational Site

Gifu, 503-8502, Japan
GSK Investigational Site

Gunma, 377-0280, Japan
GSK Investigational Site

Hokkaido, 060-8648, Japan
GSK Investigational Site

Kyoto, 602-8566, Japan
GSK Investigational Site

Kyoto, 603-8151, Japan
GSK Investigational Site

Osaka, 565-0871, Japan
GSK Investigational Site

Tokyo, 108-8639, Japan
GSK Investigational Site

Amersfoort, 3813 TZ, Netherlands
GSK Investigational Site

Gdansk, 80-214, Poland
GSK Investigational Site

Kaluga, 248007, Russia
GSK Investigational Site

Gyeonggi-do, 10408, South Korea
GSK Investigational Site

Hwasun, 58128, South Korea
GSK Investigational Site

Incheon, 21565, South Korea
GSK Investigational Site

Seongnam-si Gyeonggi-do, 13620, South Korea
GSK Investigational Site

Seoul, 03080, South Korea
GSK Investigational Site

Seoul, 05505, South Korea
GSK Investigational Site

Seoul, 06591, South Korea
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

Barcelona, 08916, Spain
GSK Investigational Site

L'Hospitalet de Llobrega, 08908, Spain
GSK Investigational Site

Málaga, 29004, Spain
GSK Investigational Site

PamplonaNavarra, 31008, Spain
GSK Investigational Site

Pozuelo de AlarcOn Madr, 28223, Spain
GSK Investigational Site

Santiago de Compostela, 15706, Spain
GSK Investigational Site

Dundee, DD1 9SY, United Kingdom
GSK Investigational Site

London, W12 0NN, United Kingdom

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA